<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280354</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00297;qu18Egli3</org_study_id>
    <nct_id>NCT04280354</nct_id>
  </id_info>
  <brief_title>Molecular Biomarkers for Sepsis</brief_title>
  <official_title>Prospective Study to Discover New Biomarkers for Early Detection of Sepsis and Prediction of Sepsis-related Mortality in Patients With Severe Community Acquired Pneumonia (sCAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Personalized Health Network (SPHN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Personalized Health and Related Technologies (PHRT) initiative of ETH Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center observational case-control study in Intensive Care Unit (ICU) patients is
      to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP)
      -associated sepsis at an earlier stage and predict sepsis-related mortality. Patients with
      sCAP (cases) will be profoundly characterized over time regarding the development of sepsis
      and compared with control patients. The mechanisms and influencing factors on the clinical
      course will be explored with most modern -omics technologies allowing a detailed
      characterisation. These data will be analysed using machine learning algorithms and
      multi-dimensional mathematical models.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of sepsis</measure>
    <time_frame>within 7 days after study inclusion</time_frame>
    <description>Sepsis detection based on new discovered digital biomarkers will be compared to classical sepsis-3 criteria (with an increase of the sequential organ failure assessment (SOFA) score of 2 or larger score points).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sepsis related mortality</measure>
    <time_frame>within 7 days after study inclusion</time_frame>
    <description>Prediction of sepsis related mortality (with &gt;80% sensitivity and specificity at least 24h prior to event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to sepsis detection (minutes after Intensive Care Unit (ICU) admission)</measure>
    <time_frame>within 7 days after study inclusion</time_frame>
    <description>Time to sepsis detection (minutes after ICU admission) based on machine learning</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Community-acquired Pneumonia (sCAP)</condition>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>patients with severe community acquired pneumonia (cases)</arm_group_label>
    <description>Cases: Patients with severe community acquired pneumonia with required ICU admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients without pneumonia or sepsis (controls)</arm_group_label>
    <description>Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever &gt;38°C, C reactive Protein (CRP) &gt;100mg/L, no infection focus expected in ≥ 24h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare data patterns by data-driven algorithms to determine sepsis</intervention_name>
    <description>compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis</description>
    <arm_group_label>patients with severe community acquired pneumonia (cases)</arm_group_label>
    <arm_group_label>patients without pneumonia or sepsis (controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare data patterns by data-driven algorithms to predict sepsis-related mortality</intervention_name>
    <description>compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality</description>
    <arm_group_label>patients with severe community acquired pneumonia (cases)</arm_group_label>
    <arm_group_label>patients without pneumonia or sepsis (controls)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All samples will be stored in a biobank on sepsis. In particular serum and DNA samples of
      hosts will be stored for at least 10 years to answer subsequent research questions.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients fulfilling the WHO-definition of a severe community acquired pneumonia
        (sCAP, cases) and patients with an inflammatory phenotype (controls) requiring intensive
        care medicine.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to the ICU of one of the participating centers.

          -  Cases: severe community acquired pneumonia with requirement for ICU admission.

          -  Controls: Clinical phenotype of inflammation not due to suspected sepsis In addition,
             control patients will be patients with fever &gt;38°C, CRP &gt;100mg/L, no infection focus
             expected in ≥ 24h.

          -  All required sample types can most likely be collected within the first 24h visits.

          -  Expected ICU stay of more than 24h.

        Exclusion Criteria:

          -  Admission to the hospital within the prior 14 days.

          -  Patients with psychosis

          -  Evidence of a hospital acquired pneumonia.

          -  One of the following respiratory conditions: Acute exacerbation of chronic obstructive
             pulmonary disease (COPD) or bronchiectasis, acute severe asthma, aspiration pneumonia,
             tuberculosis, clinical suspected viral pneumonia without bacterial infection,
             cardiogenic pulmonary oedema.

          -  Patients with an acute respiratory distress Syndrome (ARDS).

          -  Patient which can be managed as outpatients and do not require an ICU.

          -  Patient where a transmission to another institution is likely within the next 24h.

          -  Documented rejection of the general consent or participation to research in general.

          -  Patients with a palliative situation and a life expectancy due to other diseases (e.g.
             progressed cancer) less than 28 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Egli, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Microbiology, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian Egli, PD Dr.</last_name>
    <phone>+41 61 556 57 49</phone>
    <email>adrian.egli@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Battegay Manuel, Prof. Dr.</last_name>
    <phone>+41 61 328 60 72</phone>
    <email>Manuel.Battegay@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Bacteriology and Mycology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Adrian Egli, PD Dr. Dr.</last_name>
      <phone>+41 61 556 57 49</phone>
      <email>adrian.egli@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Hospital Epidemiology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuel Battegay, Prof Dr med</last_name>
      <phone>+41 61 328 60 72</phone>
      <email>manuel.battegay@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit; University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Marsch, Prof. Dr. MD</last_name>
      <phone>+41 61 328 62 35</phone>
      <email>stephan.marsch@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Martin Siegemund, Prof. Dr. med</last_name>
      <phone>+41 61 328 61 14</phone>
      <email>martin.siegemund@usb.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute for Infectious Diseases, University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen Leib, Prof. Dr. MD</last_name>
      <phone>+41 31 632 49 49</phone>
      <email>Stephen.leib@ifik.unibe.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Hospital Epidemiology, University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Hansjakob Furrer, Prof.Dr.med</last_name>
      <phone>+41 31 632 25 25</phone>
      <email>hansjakob.furrer@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Jakob, Prof. Dr. MD</last_name>
      <phone>+41 31 632 53 00</phone>
      <email>Stephan.jakob@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Hospital Epidemiology, University Hospital Geneva</name>
      <address>
        <city>Geneva,</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent Kaiser, Prof. Dr. MD</last_name>
      <phone>+41 22 372 98 00</phone>
      <email>Laurent.kaiser@huge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Bacteriology, University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques Schrenzel, Prof Dr med</last_name>
      <phone>+41 22 372 33 11</phone>
      <email>Jacques.schrenzel@huge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme Pugin, Prof. Dr. MD</last_name>
      <phone>+41 22 379 71 11</phone>
      <email>Jerome.pugin@huge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Microbiology, University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilbert Greub, Prof. Dr. MD</last_name>
      <phone>+41 21 314 49 79</phone>
      <email>gilbert.greub@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Hospital Epidemiology , University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Calandra, Prof. Dr. MD</last_name>
      <phone>+41 21 314 10 10</phone>
      <email>Thierry.calandra@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Eckert, Prof. Dr. MD</last_name>
      <phone>+41 21 314 30 38</phone>
      <email>philipp.eckert@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases and Hospital Epidemiology, University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Annelies Zinkernagel, Prof. Dr. med</last_name>
      <phone>+ 41 44 255 12 59</phone>
      <email>annelies.zinkernagel@uzh.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Medical Microbiology, University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Reinhard Zbinden, Prof. Dr. MD</last_name>
      <phone>+41 44 634 26 08</phone>
      <email>rzbinden@imm.uzh.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Reto Schüpbach, Prof. Dr. MD</last_name>
      <phone>+41 44 255 10 92</phone>
      <email>reto.schuepbach@uhz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Community-acquired Pneumonia</keyword>
  <keyword>biomarker</keyword>
  <keyword>clinical data warehouse (CDWH)</keyword>
  <keyword>machine learning</keyword>
  <keyword>data-driven algorithms</keyword>
  <keyword>multi-dimensional modelling</keyword>
  <keyword>sepsis-related mortality</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

